Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

Massimo Caracciolo¹, Sebastiano Macheda², Demetrio Labate², Marco Tescone², Stefano La Scala³, Eugenio Vadala³, Rosalba Squillaci³, Francesco D’Aleo³, Antonella Morabito⁴, Cristina Garreffa⁵, Maria Concetta Marciano⁵ and Esther N. Oliva⁶

¹ UOSD Terapia Intensiva Post-Operatoria, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, ² Intensive Care Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, ³ Dipartimento di Microbiologia e Virologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, ⁴ Central Pharmacy, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, ⁵ UOC Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, ⁶ Hematology Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cell surface density of CD56. Cytokine levels are inversely correlated with lymphocyte count, therefore cytokine release syndrome may be an impediment to the adaptive immune response against SARS-CoV-2 infection. Canakinumab, a monoclonal antibody targeting IL-1β, is under investigation for the treatment of severe SAR-CoV-2 infection. An 85 year old male presenting in our hospital with COVID-19, whose condition was complicated by acute respiratory distress syndrome and cardiac and renal failure (with oliguria) after 25 days of hospitalization, was intubated and received canakinumab for compassionate use. On the next day, diuresis recovered and conditions improved: high IL-6 levels and NK cells expressing CD56bright (associated with cytokine release) were significantly reduced giving rise to NK CD56dim. Patient died on day 58 with pulmonary bacterial superinfection and persistent SARS-CoV-2 positivity. In conclusion, canakinumab rescued a high risk, very elderly patient, from multiorgan damage complicating COVID-19. It may represent an useful treatment in severe cases.

Keywords: COVID-19, SARS-CoV-2, canakinumab, IL-1, IL-6, cytokine storm, natural killer, acute respiratory distress syndrome

INTRODUCTION

SARS-CoV-2 is responsible for the current pandemic of coronavirus disease 2019 (COVID-19). Patients present with fever, dry cough, dyspnea, and pneumonia (1). Some patients (approximately 15%), prevalently elderly and with comorbidities, develop serious multiple organ inflammation and acute respiratory distress syndrome (ARDS) (2–4) and require intensive care unit (ICU) admission (3, 4).

The immune response, including the release of pro-inflammatory cytokines and activation of T cells, are essential for controlling the viral spread, inflammation, and tissue renewal
The damaged host cell releases proteins that induce the production of pro-inflammatory cytokines by nearby cells. Monocytes, macrophages, and T cells are attracted to the site of infection, establishing a pro-inflammatory feedback circuit. When the immune response is hampered, the excessive pro-inflammatory cytokines in the lungs are responsible for lung tissue damage and the cytokine storm (CS), or macrophage activation syndrome (MAS), leading to multi-organ damage.

Severe cases with CS progress to ARDS (7, 8). The mechanisms leading to such complications are complex and still under investigation. Many features of COVID-19 resemble MAS triggered by viral infection (8, 9). In fact, SARS-CoV-2 infection is associated with high levels of cytokines and, interestingly, levels of IL-6 have been reported to be correlated with mortality (10). Furthermore, in severe cases, a reduction of natural killer cells and other T lymphocytes, has been observed. Cytokine levels are inversely correlated with lymphocyte count, therefore CS may be an impediment to the adaptive immune response against SARS-CoV-2 infection (6, 11). Moreover, the severity of COVID-19 is correlated with NK subsets distinguished according to the cell surface density of CD56. In fact, CD56bright subset increases with severity. CD56dim NK cells physiologically comprise around 90% of NK cells in peripheral blood and are frequently described as the most cytotoxic, whereas CD56bright NK cells are abundant cytokine producers (12, 13).

Interleukin-1 (IL-1) activates the expression of several pro-inflammatory genes. IL-1β induces inflammation during infection and autoimmunity (14). IL-1β is released by various cell types, including macrophages (15, 16). Canakinumab, a monoclonal antibody targeting IL-1β, is approved for use in rheumatologic disorders1. Based on the mechanism of action of canakinumab, the drug is under investigation for the treatment of severe SAR-CoV-2 infection.

We present a case of an 85 year old male presenting with COVID-19, complicated by ARDS and cardiac and renal failure, rescued by canakinumab. An indication for compassionate use for COVID-19 during the current pandemic and approval from the local ethics committee was obtained in our center.

CASE DESCRIPTION

Patient was admitted to hospital on March 23, 2020, presenting with fever (38.5°C), hypoxemia (p02 = 61 mmHg), cough, and dyspnea. Medical history revealed only mild arterial hypertension treated with amlodipine and prostatic hypertrophy not requiring treatment. SARS-CoV-2 swab was positive. Chest X-ray showed an interstitial lung pattern and small left pleural effusion. Renal and liver biochemistry were normal. Noteworthy, the patient presented lymphopenia. Reactive C Protein (RCP) was 139 mg/L. Coagulation tests were normal except for Fibrinogen 619 mg/dl and D-dimers 409 ng/mL. He was at first treated in the COVID ward and received broad spectrum antibiotics, hydroxychloroquine, and oxygen therapy with Venturi mask with 30% FiO2 setting. On day 3, a chest computerized tomography (CT) without contrast showed severe lung injury (Figure 1).

On day 4, though the fever had subsided, his respiratory condition deteriorated and continuous positive airway pressure (CPAP) non-invasive ventilation with 40% FiO2 setting and positive end-expiratory pressure (PEEP) 10 cmH2O was initiated, together with azitromycin, enoxaparin sodium and lopinavir/ritonavir. On day 5, tocolizumab 8 mg/kg was administered intravenously (within a clinical trial) repeated after 12 h, while continuing hydroxychloroquine, azitromycin and enoxaparin. On day 23, his conditions precipitated with presentation of ARDS, a PaO2/FiO2 ratio (PF) of 103 (FiO2 setting 60%, p02 62 mmHg) and severe arterial hypertension. He was transferred to the Intensive Care Unit (ICU) in an unblubilated and non-collaborative condition, so that he was sedated with dexmedetomidine while continuing CPAP ventilation. On day 24, patient presented oliguria with acute renal and cardiac failure and progressive respiratory failure. He was intubated and received assisted mechanical ventilation together with furosemide continuous intravenous infusion and vasopressor amines.

On day 25, the patient’s son was informed of the severity of the patient’s clinical conditions and of the risks and benefits of canakinumab treatment. He signed informed consent to administer treatment, to process and publish all relevant clinical research data and potentially identifying information. Canakinumab was administered at a single 300 mg s.c. dose on days 25 and 31.

DIAGNOSTIC ASSESSMENT

To evaluate the biochemical effects of canakinumab, general laboratory chemistry, IL-6, and immunophenotype were collected before and after first and second administration.

1https://www.drugs.com/pro/ilaris.html#s-34067-9
The drug was well tolerated in the short term, and on the day following the first administration, the patient’s diuresis normalized and renal function improved gradually without full recovery (on day 53, creatinine level reached 88 µmol/L). The findings are summarized in Table 1.

During hospitalization, the patient underwent periodical microbiological surveillance tests. SARS-Cov-2 genome was evaluated by the Microbiology and Virology laboratory of our hospital. Samples from upper (nasopharyngeal) and lower (bronchoalveolar, bronchoaspirate, and tracheal aspirate) airways were collected and processed within 24 h. RNA-COVID 19 was evaluated using an Allplex 2019-nCoV assay that identifies three different target genes: E (envelope), RdRp (RNA-dependent RNA polymerase), and N (nucleoprotein gene). Based on the interpretation criteria, detection of one or more genes was interpreted as positive COVID-19. There was a high viral replication persisting on Day 43.

On day 31, as the respiratory conditions did not improve significantly, the Film Array Pneumonia detected the presence of bacterial infection caused by Acinetobacter C.B. Complex – 107 copies/mL – and Pseudomonas Aeruginosa – 106 copies/mL, treated initially with the association of Piperacillin + Tazobactam together with Cotrimoxazole provided intravenously QID, followed by Colistin 3000000 aerosol BID, then with Ceftazidime/Avibactam intravenous TID and finally with Doxycycline 100 mg intravenous BID (the latter ongoing).

The initial chest CT scan on Day 13 and X-rays performed before First administration (Day 23) and after Second administration (Day 38) are shown in Figure 2.

**DISCUSSION**

Canakinumab is an IL-1 antagonist indicated to treat autoinflammatory disorders. Severe COVID-19 cases show symptoms associated with an excessive release of cytokines (17, 18).

The IL-1 cytokine family plays an important role in regulating inflammation and is produced in response to inflammatory stimuli and infections. IL-1 production requires inflammasome/Caspase-1-dependent processing. It mediates its effects by binding to its receptor to activate downstream signaling which activates MAPKs and NF-kappa B, leading to the expression of pro-inflammatory mediators that drives the IL-6 signaling pathway.

---

**TABLE 1** | The laboratory findings before (day 23) and after the First (day 28) and Second (day 42) administrations of canakinumab.

| Variable                        | Before | After First | After Second |
|---------------------------------|--------|-------------|--------------|
| Hemoglobin (Hb) g/dL            | 12.0   | 11.3        | 8.7          |
| White Blood Cell count (WBC) x 10^9/L | 4.4    | 6.5         | 12.4         |
| Neutrophils-bands (Neutroph) x 10^9/L | 3.4    | 5.8         | 10.3         |
| Lymphocytes (Lymph) x 10^9/L    | 0.5    | 0.2         | 0.5          |
| Platelet count (PLT) x 10^9/L   | 135    | 107         | 291          |
| D-dimer (D-d) mmol/L            | 2.1    | 1.9         | 3.2          |
| Creatinine (Cr) µmol/L          | 44     | 124         | 97           |
| CRP mg/L                        | 3.1    | 10.2        | 156.0        |
| Lactate dehydrogenase (LDH) µkat/L | 5.0    | 3.8        | 3.8          |
| Alkaline phosphatase µkat/L     | 1.6    | 1.9         | 1.9          |
| Alanine aminotransferase (ALT) µkat/L | 1.0    | 0.5        | 0.2          |
| Aspartate aminotransferase (AST) µkat/L | 0.5    | 0.4        | 0.4          |
| γ-Glutamyltransferase (GGT) µkat/L | 0.4    | 0.4        | 0.5          |
| Serum IL-6, IU/ml               | 424.6  | 46.2        | 75.2         |
| Immunophenotype, cells/µL       | 402    | 172         | 114          |
| Lymphocyte T                    | 309    | 117         | 74           |
| CD3+                            | 95     | 56          | 41           |
| Lymphocyte B CD19+              | 31     | 32          | 34           |
| CD16+CD56+                      | 111    | 77          | 18           |
| NK CD66+                        | 57     | 66          | 109          |
| NK CD66BRIGHT                   | 42     | 1           | 2            |
| CD4/CD8 Ratio                   | 3      | 2           | 2            |

**FIGURE 2** | (A) Before the first administration of canakinumab, the chest X-ray shows interstitial changes, ground glass opacities, and multifocal and bilateral effusions. (B) After second administration, the chest X-ray shows the extensive bilateral opacities and bilateral effusions, concomitant to bacterial superinfection.
IL-6 significantly contributes to MAS. Its levels increase with the severity of COVID-19 (9, 19, 20) and the area of pulmonary infiltration (≥ 50%) in patients with ARDS, together with specific lymphocyte subsets (21). Though the present case had received tocilizumab prior to canakinumab, IL-6 level remained high, postulating that tocilizumab be insufficient to rescue the patient from the subsequent cytokine storm. In our patient, IL-6 and NK CD56bright both decreased after treatment with canakinumab, suggesting that canakinumab, by interfering with IL-1, reduces IL-6. Following the Second administration, IL-6 and CRP levels increased which can be explained with the development of superimposed pulmonary bacterial infection.

Several immunotherapeutic drugs are promising for the treatment of the cytokine storm associated with COVID-19 (22). Amongst these, anakinra, an IL-1 receptor antagonist, saltuximab, an IL-6 antagonist, and sarilumab, an IL-6 receptor antagonist, are undergoing Phase 3 stage development (23).

However, canakinumab treatment is associated with adverse events, mainly an increased incidence of serious infections. In fact, IL-1β physiologically contributes to host defense against infection by enhancing the antimicrobial action of phagocytes and inducing Th1 and Th17 adaptive immune responses (24). In our case, the patient survived the MAS, but developed bacterial pulmonary superinfection, which was the final cause of death on day 58. This case represents the first published report of canakinumab for the treatment of multiorgan damage associated with COVID-19.

PATIENT PERSPECTIVE

Excessive cytokine release induces severe complications and worsens the prognosis in COVID-19. There are numerous ongoing trials to find treatments that target virus and/or inflammation. Until an effective treatment is found, in this scenario, Canakinumab due to its blocking action of proinflammatory activity by IL-1β can constitute a potential useful treatment in the modulation of hyperinflammatory symptoms, for a subgroup of patients with COVID-19, that resemble the cytokine storm in patients with MAS. The active involvement of immunologists in the clinic and in clinical trials may improve patient outcomes.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato Etico Sezione Sud – Regione Calabria. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MC, EO, and DL drafted the initial manuscript. CG performed flow cytometry. FD’A performed microbiological testing. MM performed cytokine tests. All authors reviewed and revised the manuscript and have read and agreed to the published version of the manuscript to the work reported.

ACKNOWLEDGMENTS

Novartis provided compassionate use of Canakinumab for the case described.

REFERENCES

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3.
2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. (2020) 8:420–2.
3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9.
4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20.
5. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. (2014) 14:36–49. doi: 10.1038/nri3581
6. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. (2020) 92:424–32.
7. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. (2014) 5:69–86.
8. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. (2020) 12:ciaa248.
9. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. (2020) [Preprint]. doi: 10.1101/2020.02.10.20021832
10. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonificio AE, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19. J Autoimmun. (2020) 17:102468. doi: 10.1016/j.jaut.2020.102468
11. Pedersen F, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. (2020) 130:2202–5.
12. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. (2020) 92:424–32.
13. Cooper MA, Fehninger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. (2001) 22:633–40.
14. Vivier E, Tomasello E, Baratin M, Walter T, Ugolini S. Functions of natural killer cells. Nat Immunol. (2008) 9:503–10.
15. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. (2004) 4:378–85.
16. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol. (2003) 521:1–21.
17. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev. (2009) 60:57–64. doi: 10.1016/j.brainresrev.2008.12.020
18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62.
19. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4.
20. Lee CR, Kang JA, Kim HE, Choi Y, Yang T, Park SG. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance. FEBS Lett. (2016) 590:358–68.
21. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. *Front Immunol.* (2019) 10:119.

22. Wang W, He J, Lie P, Huang L, Wu S, Lin Y, et al. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. *MedRxiv.* (2020) [Preprint]. doi: 10.1101/2020.02.26.20026989

23. Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct immunotherapies for the management of severely ill COVID-19 Patients. *Cell Rep Med.* (2020) 1:100016. doi: 10.1016/j.xcrm.2020.100016

24. Van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LAB. Inflammasome activation and IL-1β and IL-18 processing during infection. *Trends Immunol.* (2011) 32:110–6.

**Conflict of Interest:** EO reports personal fees from Novartis, during the conduct of the study.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Caracciolo, Macheda, Tescione, La Scala, Vadala, Squillaci, D’Aleo, Morabito, Garreffa, Marciano and Oliva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.